MedTrace Logo

Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis

NCT00886925 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2012-12-17

No results posted yet for this study

Summary

The purpose of this study is to determine whether the administration of albumin in addition to the standard care is effective in the treatment of an episode of hepatic encephalopathy in patients with cirrhosis.

Conditions

  • Hepatic Encephalopathy

Interventions

DRUG

Albumin

Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.

DRUG

Sodium chloride 0.9%

Day 0: 400-600 ml. Day 2: 200-400 ml.

Sponsors & Collaborators

  • Hospital Universitari Vall d'Hebron Research Institute

    lead OTHER

Principal Investigators

  • Juan Cordoba, MD · Hospital Vall d'Hebron

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00886925 on ClinicalTrials.gov